CHEST Poster Presentations
MediciNova’s intravenous beta-agonist MN-221 program had seven poster presentations scheduled during the Annual Meeting of the American College of Chest Physicians in Vancouver, Canada in November 2010. The presentations are related to MediciNova’s development of MN-221 for potential utility in acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD). Please click on the poster titles to view.
- MN-221-CL-004: Evaluation of MN-221 (bedoradrine), a novel, highly selective beta2-adrenergic receptor agonist in mild to moderate asthma via intravenous infusion (Poster #145)
- MN-221-CL-005: Comparison of Administration Rates of MN-221 (bedoradrine), a Novel, Highly Selective Beta2 Receptor Agonist in Patients with Stable Moderate to Severe Asthma (Poster #143)
- MN-221-CL-006: Reduced Hospital Admission and Improved Pulmonary Function Following Intravenous MN-221 (bedoradrine), a Novel Highly Selective Beta2-Adrenergic Receptor Agonist, Adjunctive to Standard of Care in Severe Acute Exacerbation of Asthma (Poster #144)
- Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling and Simulation Support the Novelty of MN-221, a Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Asthma (Poster #146)
- MN-221 FY08-065: Cardiovascular Effects of i.v. MN-221 (bedoradrine) Administered with nebulized Albuterol in Dogs (Poster #147)
- Pharmacokinetics and Pharmacodynamics of MN221, a Novel Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Chronic Obstructive Pulmonary Disease (Poster #685)
- MN-221-CL-010: Intravenous MN-221, a Novel, Highly Selective Beta2 Adrenergic Receptor Agonist, Improves Lung Function in Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients (Poster #686)